BioCryst Pharmaceuticals (BCRX) News Today $7.28 +0.24 (+3.42%) As of 10:09 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period BioCryst Pharmaceuticals' (BCRX) Outperform Rating Reiterated at Royal Bank of CanadaApril 14 at 2:56 AM | americanbankingnews.comBioCryst Pharmaceuticals' (BCRX) Outperform Rating Reaffirmed at Royal Bank of CanadaRoyal Bank of Canada reaffirmed an "outperform" rating and issued a $11.00 target price on shares of BioCryst Pharmaceuticals in a report on Friday.April 13 at 11:29 AM | marketbeat.comNorges Bank Acquires Shares of 524,804 BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Norges Bank bought a new position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 524,804 shares of the biotechnology company's stock, valued at approximateApril 13 at 4:03 AM | marketbeat.comBioCryst Pharmaceuticals' (BCRX) "Buy" Rating Reiterated at Needham & Company LLCApril 13 at 2:05 AM | americanbankingnews.comExecutive reshuffles: CVS, NNDM, and DBXApril 12 at 4:14 PM | msn.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Given "Buy" Rating at Needham & Company LLCNeedham & Company LLC reaffirmed a "buy" rating and set a $15.00 price target on shares of BioCryst Pharmaceuticals in a research note on Thursday.April 12 at 10:59 AM | marketbeat.comBioCryst CEO to serve as interim CFOApril 11, 2025 | markets.businessinsider.comBioCryst (BCRX) Gets a Buy from NeedhamApril 10, 2025 | markets.businessinsider.comBioCryst Appoints CEO as Interim CFO Amid TransitionApril 10, 2025 | tipranks.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Recommendation of "Moderate Buy" by AnalystsShares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) have been given an average rating of "Moderate Buy" by the seven research firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and six have assApril 9, 2025 | marketbeat.comTrexquant Investment LP Reduces Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Trexquant Investment LP lowered its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 43.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 494,356 shares of the biotechnology companyApril 8, 2025 | marketbeat.comVanguard Group Inc. Has $164.62 Million Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Vanguard Group Inc. increased its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 7.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 21,890,422 shares of the biotechnology coApril 8, 2025 | marketbeat.comKLP Kapitalforvaltning AS Takes Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)KLP Kapitalforvaltning AS acquired a new position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 39,800 shares of the biotechnology company'sApril 8, 2025 | marketbeat.comSchroder Investment Management Group Buys 438,887 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Schroder Investment Management Group grew its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 523.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 522,657 shares of the biApril 7, 2025 | marketbeat.comCinctive Capital Management LP Trims Stock Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Cinctive Capital Management LP lowered its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 29.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 194,386 shares of the biotApril 6, 2025 | marketbeat.comRBC Capital Sticks to Their Buy Rating for BioCryst (BCRX)April 5, 2025 | markets.businessinsider.comBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 4, 2025 | globenewswire.comBioCryst Pharmaceuticals Inc (BCRX) to Present at 24th Annual Needham Virtual Healthcare ConferenceApril 2, 2025 | gurufocus.comBioCryst to Present at Upcoming Investor ConferenceApril 2, 2025 | globenewswire.comBCRX Crosses Below Key Moving Average LevelApril 2, 2025 | nasdaq.comKnott David M Jr Acquires 58,000 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Knott David M Jr lifted its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 15.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 440,000 shares of the biotechnology company's stock after acquirApril 2, 2025 | marketbeat.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Short Interest UpdateBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) was the target of a large growth in short interest in March. As of March 15th, there was short interest totalling 19,770,000 shares, a growth of 23.5% from the February 28th total of 16,010,000 shares. Approximately 10.0% of the shares of the company are short sold. Based on an average trading volume of 3,140,000 shares, the short-interest ratio is presently 6.3 days.April 2, 2025 | marketbeat.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Acquired by Prudential Financial Inc.Prudential Financial Inc. grew its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 10.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 983,033 shares of thMarch 31, 2025 | marketbeat.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Sold by Segall Bryant & Hamill LLCSegall Bryant & Hamill LLC trimmed its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 4.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,422,196 shares of the biotechnoMarch 28, 2025 | marketbeat.comHillsdale Investment Management Inc. Increases Stock Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Hillsdale Investment Management Inc. raised its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 65,213.3% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 542,100 shares of the biotechnology company's stockMarch 24, 2025 | marketbeat.comIntech Investment Management LLC Raises Stock Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Intech Investment Management LLC raised its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 80.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 97,793 shares of the biotechnology company'sMarch 24, 2025 | marketbeat.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Up 3.7% - Here's What HappenedBioCryst Pharmaceuticals (NASDAQ:BCRX) Trading 3.7% Higher - Time to Buy?March 22, 2025 | marketbeat.comSemanteon Capital Management LP Purchases 48,184 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Semanteon Capital Management LP grew its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 32.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 197,760 sharesMarch 22, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Has $14.89 Million Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Charles Schwab Investment Management Inc. boosted its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 4.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,979,992 shMarch 21, 2025 | marketbeat.comNorth Carolina biotech sues to block copies of $400M drugMarch 20, 2025 | bizjournals.comInstitutional investors control 75% of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and were rewarded last week after stock increased 4.9%March 18, 2025 | uk.finance.yahoo.comConnor Clark & Lunn Investment Management Ltd. Sells 48,460 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Connor Clark & Lunn Investment Management Ltd. trimmed its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 7.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 633,864 shares of the biotecMarch 17, 2025 | marketbeat.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Purchased by Jupiter Asset Management Ltd.Jupiter Asset Management Ltd. increased its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 10.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,177,929 shares of the biotechnoloMarch 14, 2025 | marketbeat.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Recommendation of "Moderate Buy" from BrokeragesBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) has been given an average recommendation of "Moderate Buy" by the seven research firms that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and six have assignedMarch 14, 2025 | marketbeat.comPrincipal Financial Group Inc. Sells 393,607 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Principal Financial Group Inc. reduced its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 95.7% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 17,807 shares of the biotechnMarch 9, 2025 | marketbeat.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Down 4.4% - What's Next?BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Down 4.4% - What's Next?March 6, 2025 | marketbeat.comBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 6, 2025 | globenewswire.comBioCryst CFO Anthony Doyle to resign, effective April 9March 4, 2025 | markets.businessinsider.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Sold by Fisher Asset Management LLCFisher Asset Management LLC lowered its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 4.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 3,182,617 shares of the biotechnology company's stockMarch 4, 2025 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Krystal Biotech (KRYS) and BioCryst (BCRX)March 3, 2025 | markets.businessinsider.comIeq Capital LLC Takes Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Ieq Capital LLC acquired a new position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 29,436 shares of the biotechnology company's stockMarch 2, 2025 | marketbeat.comIs BioCryst Pharmaceuticals, Inc. (BCRX) the Best Small-Cap Stock to Buy Now?March 1, 2025 | insidermonkey.comResearch Analysts Offer Predictions for BCRX Q1 EarningsBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - Equities researchers at Wedbush issued their Q1 2025 earnings per share estimates for shares of BioCryst Pharmaceuticals in a research report issued on Tuesday, February 25th. Wedbush analyst L. Chico forecasts that the biotechnology coFebruary 27, 2025 | marketbeat.comBioCryst: Orladeyo's Expansion Is Just Getting StartedFebruary 27, 2025 | seekingalpha.comBioCryst: Hold Steady As Orladeyo Builds, But Competition Heats UpFebruary 26, 2025 | seekingalpha.comEvercore ISI Sticks to Their Buy Rating for BioCryst (BCRX)February 26, 2025 | markets.businessinsider.comAnalysts Are Updating Their BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Estimates After Its Yearly ResultsFebruary 26, 2025 | finance.yahoo.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q4 2024 Earnings Call TranscriptFebruary 26, 2025 | msn.comBioCryst: Upgrading On Strong 2024 Orladeyo Sales, But I Remain SkepticalFebruary 25, 2025 | seekingalpha.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Given Outperform Rating at Royal Bank of CanadaRoyal Bank of Canada restated an "outperform" rating and set a $11.00 price target (up from $10.00) on shares of BioCryst Pharmaceuticals in a research report on Tuesday.February 25, 2025 | marketbeat.com Remove Ads Get BioCryst Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address BCRX Media Mentions By Week BCRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BCRX News Sentiment▼0.720.80▲Average Medical News Sentiment BCRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BCRX Articles This Week▼136▲BCRX Articles Average Week Remove Ads Get BioCryst Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies IONS News Today ALKS News Today FOLD News Today LGND News Today DVAX News Today MNKD News Today CLDX News Today INVA News Today NVAX News Today OPK News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BCRX) was last updated on 4/15/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredElon’s Silver Play? Trump Clears the PathNothing is confirmed—yet. But Musk has disrupted every industry he's touched, and Trump's policies make the ti...Priority Gold | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioCryst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioCryst Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BCRX Stock Free BCRX Stock Alerts